-
Featured Authors
-
Archives
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Author Archive: BIOtechNOW Editor
FDA Check-Up: Drug Development and Manufacturing Challenges
I have over 27 years of experience in the biotechnology and pharmaceutical industry. My current company, OncoMed Pharmaceuticals, is working at the cutting edge of oncology research, focused on antibodies that target a specific set of cells within tumors, known as tumor initiating cells, that drive the growth of the tumor and can differentiate into various cell types within the tumor. Currently, we have five products in clinical development in over 13 completed or ongoing Read More >
The Arrival of Actionable Personalized Medicine
The pace of implementation of next-generation sequencing (NGS) in a clinical context, which almost rivals the development of the technology over the past decade, is driving the cost of a full genome sequence down to just a few thousand dollars. Diagnostic companies and medical centers are now routinely offering comprehensive genome analysis, as evidenced by the recent report from Baylor College of Medicine in the New England Journal of Medicine on the first 250 patients Read More >
New Cancer Treatments Seek to Give the Immune System Superpowers
Melanoma is scary. It is aggressive, spreads quickly to far-away organs with the stealth and cunning of the most adept villain, and it is increasingly striking young people-it is now the most common form of cancer diagnosed in women 25-29. But the “good guys” are fighting back with increasing success. As the CEO of the Melanoma Research Alliance (MRA), a patient-focused, science-based organization dedicated to fighting this deadly skin cancer, I see signs every day Read More >
Fighting Blindness through Sound Investments in Research
Since 1971, the Foundation Fighting Blindness has raised more than half a billion dollars in support of its mission to put an end to retinal diseases. Those diseases affect more than 10 million Americans at risk of vision impairment, legal blindness or total blindness. Because age-related macular degeneration (AMD), one of the diseases we target, is the leading cause of blindness in people over 55, and because the Baby Boomer population is aging, that number Read More >
Uniting To Accelerate Pediatric Medicine
Drug companies inherently absorb significant risk when developing compounds and biologics for clinical use. A recent article suggests that only one out of every 12 drugs that enters clinical trials succeeds and the cost of a drug successfully reaching the market now exceeds an average of $5 billion when you add up the cost of all those that failed along the way. For many indications, such as Alzheimer’s and autism, the need for new treatments Read More >
